The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
Asian equities were mostly lower on Tuesday, with US markets closed for Martin Luther King Jr. Day, as global sentiment weakened following fresh tariff threats from Donald Trump.
Avacta Group plc reported strong operational progress in 2025, having raised £22.5m in equity to support its research and development programmes. The company ended the year with unaudited cash reserves
Oil prices moved higher and Asian equity markets were mostly stronger, led by a sharp rally in Japan after Wall Street closed at fresh record levels.
Asian equities were mostly lower on Thursday as Wall Street’s early New Year rally lost momentum.
Asian markets were mixed as investors balanced expectations around global interest rates with lingering uncertainty over recent developments in Venezuela and geopolitical risk.
Asian markets delivered a strong performance on Tuesday, led by record-setting gains in Japan, as momentum from Wall Street’s rally continued to ripple through global equities.
Oil prices retreated while precious metals surged after the US captured Venezuelan president Nicolas Maduro in a weekend raid, a development that rattled energy markets but sent investors rushing toward
Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence
Asian markets advanced after softer-than-expected US inflation data revived hopes of another interest rate cut as soon as next month.
Asian markets slipped further after a sell-off in AI-related stocks pushed US equities to their weakest session in nearly a month.
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days